Epigenetic regulation of microRNA expression in Hodgkin lymphoma

Leukemia and Lymphoma

Volumn 56, Issue 9, 2015, Pages 2683-2689

  Navarro, Alfons ^a   Díaz, Tania ^a   Cordeiro, Anna ^a   Beyá, Marina Díaz ^b   Ferrer, Gerardo ^c   Fuster, Dolors ^a   Martinez, Antonio ^c   Monzó, Mariano ^a  

^a School of Medicine   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

cell lines and animal models; chemotherapeutic approaches; Lymphoma and Hodgkin disease

Indexed keywords

DECITABINE; MICRORNA; MICRORNA 105; MICRORNA 10B; MICRORNA 126; MICRORNA 130A; MICRORNA 135B; MICRORNA 146B 5P; MICRORNA 15A; MICRORNA 17; MICRORNA 192; MICRORNA 200B; MICRORNA 203; MICRORNA 215; MICRORNA 22; MICRORNA 222; MICRORNA 25; MICRORNA 30A; MICRORNA 323 3P; MICRORNA 335; MICRORNA 342 5P; MICRORNA 34A; MICRORNA 375; MICRORNA 490 3P; MICRORNA 512 3P; MICRORNA 518E; MICRORNA 518F; MICRORNA 519A; MICRORNA 525 3P; MICRORNA 99B; UNCLASSIFIED DRUG; AZACITIDINE; TRANSCRIPTOME;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CELL PROLIFERATION; CLINICAL EVALUATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; DRUG EFFICACY; EPIGENETICS; GENE EXPRESSION REGULATION; GENE SILENCING; HODGKIN DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LYMPH NODE; LYMPHOMA CELL LINE; PRIORITY JOURNAL; PROMOTER REGION; ANALOGS AND DERIVATIVES; CLUSTER ANALYSIS; DRUG EFFECTS; GENE EXPRESSION PROFILING; GENETIC EPIGENESIS; GENETICS; METABOLISM; PATHOLOGY; REPRODUCIBILITY; TUMOR CELL LINE;

AZACITIDINE; CELL LINE, TUMOR; CLUSTER ANALYSIS; DNA METHYLATION; EPIGENESIS, GENETIC; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HODGKIN DISEASE; HUMANS; LYMPH NODES; MICRORNAS; PROMOTER REGIONS, GENETIC; REPRODUCIBILITY OF RESULTS; TRANSCRIPTOME;

EID: 84946013284     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2014.995650     Document Type: Article

References (39)

1. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009; 136: 215-233.
2. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-297.
3. Calin GA, Sevignani C, Dumitru CD, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 2004; 101: 2999-3004.
4. Deng S, Calin GA, Croce CM, et al. Mechanisms of microRNA deregulation in human cancer. Cell Cycle 2008; 7: 2643-2646.
5. Calin GA, Ferracin M, Cimmino A, et al. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 2005; 353: 1793-1801.
6. Mishra PJ, Banerjee D, Bertino JR. MiRSNPs or MiR-polymorphisms, new players in microRNA mediated regulation of the cell: introducing microRNA pharmacogenomics. Cell Cycle 2008; 7: 853-858.
7. He L, Thomson JM, Hemann MT, et al. A microRNA polycistron as a potential human oncogene. Nature 2005; 435: 828-833.
8. Suzuki HI, Yamagata K, Sugimoto K, et al. Modulation of microRNA processing by p53. Nature 2009; 460: 529-533.
9. Saito Y, Jones PA. Epigenetic activation of tumor suppressor microRNAs in human cancer cells. Cell Cycle 2006; 5: 2220-2222.
10. Esteller M. Epigenetics in cancer. N Engl J Med 2008; 358: 1148-1159.
11. Robertson KD. DNA methylation and chromatin-unraveling the tangled web. Oncogene 2002; 21: 5361-5379.
12. Rodriguez-Paredes M, Esteller M. Cancer epigenetics reaches mainstream oncology. Nat Med 2011; 17: 330-339.
13. Carmona FJ, Esteller M. DNA methylation in early neoplasia. Cancer Biomark 2011; 9: 101-111.
14. Kuppers R. The biology of Hodgkin's lymphoma. Nat Rev Cancer 2009; 9: 15-27.
15. Ushmorov A, Leithauser F, Sakk O, et al. Epigenetic processes play a major role in B-cell-specific gene silencing in classical Hodgkin lymphoma. Blood 2006; 107: 2493-2500.
16. Lujambio A, Calin GA, Villanueva A, et al. A microRNA DNA methylation signature for human cancer metastasis. Proc Natl Acad Sci USA 2008; 105: 13556-13561.
17. Lujambio A, Ropero S, Ballestar E, et al. Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer Res 2007; 67: 1424-1429.
18. Artells R, Navarro A, Diaz T, et al. Ultrastructural and immunohistochemical analysis of intestinal myofibroblasts during the early organogenesis of the human small intestine. Anat Rec 2011; 294: 462-471.
19. Furuta M, Kozaki KI, Tanaka S, et al. miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepa-Docellular carcinoma. Carcinogenesis 2010; 31: 766-776.
20. Craig VJ, Cogliatti SB, Rehrauer H, et al. Epigenetic silencing of microRNA-203 dysregulates ABL1 expression and drives Helicobacter-Associated gastric lymphomagenesis. Cancer Res 2011; 71: 3616-3624.
21. Tazawa H, Tsuchiya N, Izumiya M, et al. Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells. Proc Natl Acad Sci USA 2007; 104: 15472-15477.
22. Bueno MJ, Perez de Castro I, Gomez de Cedron M, et al. Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression. Cancer Cell 2008; 13: 496-506.
23. Van Vlierberghe P, De Weer A, Mestdagh P, et al. Comparison of miRNA profiles of microdissected Hodgkin/Reed-Sternberg cells and Hodgkin cell lines versus CD77 + B-cells reveals a distinct subset of differentially expressed miRNAs. Br J Haematol 2009; 147: 686-690.
24. Gibcus JH, Tan LP, Harms G, et al. Hodgkin lymphoma cell lines are characterized by a specific miRNA expression profile. Neoplasia 2009; 11: 167-176.
25. Navarro A, Gaya A, Martinez A, et al. MicroRNA expression profiling in classic Hodgkin lymphoma. Blood 2008; 111: 2825-2832.
26. Navarro A, Diaz T, Martinez A, et al. Regulation of JAK2 by miR-135a: prognostic impact in classic Hodgkin lymphoma. Blood 2009; 114: 2945-2951.
27. Lodygin D, Tarasov V, Epanchintsev A, et al. Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle 2008; 7: 2591-2600.
28. Chim CS, Wong KY, Qi Y, et al. Epigenetic inactivation of the miR-34a in hematological malignancies. Carcinogenesis 2010; 31: 745-750.
29. Wong KY, Liang R, So CC, et al. Epigenetic silencing of MIR203 in multiple myeloma. Br J Haematol 2011; 154: 569-578.
30. Chim CS, Wong KY, Leung CY, et al. Epigenetic inactivation of the hsa-miR-203 in haematological malignancies. J Cell Mol Med 2011; 15: 2760-2767.
31. Chim CS, Wan TS, Wong KY, et al. Methylation of miR-34a, miR-34b/c, miR-124-1 and miR-203 in Ph-negative myeloproliferative neoplasms. J Transl Med 2011; 9: 197.
32. de Souza Rocha Simonini P, Breiling A, Gupta N, et al. Epigenetically deregulated microRNA-375 is involved in a positive feedback loop with estrogen receptor alpha in breast cancer cells. Cancer Res 2010; 70: 9175-9184.
33. Grady WM, Parkin RK, Mitchell PS, et al. Epigenetic silencing of the intronic microRNA hsa-miR-342 and its host gene EVL in colorectal cancer. Oncogene 2008; 27: 3880-3888.
34. Hamfjord J, Stangeland AM, Hughes T, et al. Differential expression of miRNAs in colorectal cancer: comparison of paired tumor tissue and adjacent normal mucosa using high-Dhroughput sequencing. PLoS One 2012; 7: e34150.
35. Tsai KW, Kao HW, Chen HC, et al. Epigenetic control of the expression of a primate-specific microRNA cluster in human cancer cells. Epigenetics 2009; 4: 587-592.
36. Saba HI. Decitabine in the treatment of myelodysplastic syndromes. Ther Clin Risk Manag 2007; 3: 807-817.
37. Hollenbach PW, Nguyen AN, Brady H, et al. A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines. PLoS One 2010; 5: e9001.
38. Ru P, Steele R, Hsueh EC, et al. Anti-miR-203 upregulates SOCS3 expression in breast cancer cells and enhances cisplatin chemosensitivity. Genes Cancer 2011; 2: 720-727.
39. Hagemann S, Heil O, Lyko F, et al. Azacytidine and decitabine induce gene-specific and non-random DNA demethylation in human cancer cell lines. PLoS One 2011; 6: e17388.